May 13, 2020 / 10:23 PM / 17 days ago

BRIEF-New Combination Data For Merck's Keytruda Demonstrated Clinical Benefit In Stage III Non-Small Cell Lung Cancer

May 13 (Reuters) - Merck & Co Inc:

* NEW COMBINATION DATA FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB) DEMONSTRATED CLINICAL BENEFIT IN STAGE III NON-SMALL CELL LUNG CANCER (NSCLC) AND REINFORCE LONG-TERM SURVIVAL IN METASTATIC NSCLC

* MERCK - IN FINAL ANALYSIS OF KEYNOTE-189, KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY REDUCED RISK OF DEATH BY 44% VERSUS CHEMOTHERAPY AND AT TWO YEARS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below